TGFβ1对原发性肝癌诊断价值的Meta分析

莫晓丽; 刘洁; 诸佳瑜; 陈闯; 欧杰; 毛素菲

doi:10.3969/j.issn.1001-5256.2017.05.014

TGFβ1对原发性肝癌诊断价值的Meta分析

DOI: 10.3969/j.issn.1001-5256.2017.05.014

1. 广西中医药大学
2. 广西医科大学附属肿瘤医院中医科

基金项目:

广西科学研究与技术开发计划项目(桂科攻1598012-54)；广西自然科学基金面上项目(2014GXNSFAA118191)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2576
- HTML全文浏览量: 10
- PDF下载量: 908
- 被引次数: 0
出版历程
- 出版日期: 2017-05-20

Value of transforming growth factor-β1 in diagnosis of primary liver cancer:a meta-analysis

Guangxi University of Chinese Medicine

Research funding:

摘要

摘要:
目的采用Meta分析方法系统评价TFGβ1在原发性肝癌(以下简称肝癌)诊断中的价值。方法计算机检索Pub Med、EMBASE、Cochrane Library、中国生物医学文献数据库(CBM)、中国期刊全文数据库(CNKI)、万方数据库及维普数据库中公开发表的TGFβ1诊断原发性肝癌的文献,检索时间为数据库建库至2016年6月30日。筛选出的文献采用OQAQ量表进行评价质量。通过Stata 13.0软件进行效应量诊断比值比、阳性似然比、阴性似然比等指标合并,并绘制综合受试者工作特征曲线(SROC曲线),进行发表偏倚检验。可信度以95%可信区间(95%CI)表示。异质性检验采用Q检验和I2检验,同时进行亚组分析。结果共纳入16篇文献,合计肝癌组1124例,对照组1443例。敏感度及95%CI为0.68(0.52~0.80),特异度及95%CI为0.85(0.74~0.92),诊断比值比及95%CI为11.75(6.18~22.36);阳性似然比及95%CI为4.6(2.7~7.9),阴性似然比及95%CI为0.38(0.26~0.56),SROC曲线下面积及95%CI为0.84(0.8...
- 肝肿瘤 /
- 转化生长因子β1 /
- 诊断 /
- Meta分析
Abstract:
Objective To investigate the value of transforming growth factor-β1 (TGFβ1) in the diagnosis of primary liver cancer using a meta-analysis.Methods Pub Med, EMBASE, Cochrane Library, CBM, CNKI, Wanfang Data, and VIP were searched for articles on TGFβ1 in the diagnosis of primary liver cancer published up to June 30, 2016.The Overview Quality Assessment Questionnaire was used to evaluate the quality of articles screened out.Stata 13.0 software was used for the analysis of diagnostic odds ratio, positive likelihood ratio, and negative likelihood ratio, the summary receiver operating characteristic (SROC) curve was plotted, and publication bias was tested.The confidence level was expressed as 95% confidence interval (95% CI) .The Q test and I2 test were used for testing heterogeneity, and a subgroup analysis was also performed.Results A total of 16 articles were included, with 1124 patients in liver cancer group and 1443 patients in control group.The sensitivity was 0.68 (95% CI:0.52-0.80) and the specificity was 0.85 (95% CI:0.74-0.92) .The diagnostic odds ratio, positive likelihood ratio, and negative likelihood ratio were 11.75 (95% CI:6.18-22.36) , 4.6 (95% CI:2.7-7.9) , and0.38 (95% CI:0.26-0.56) , respectively.The area under the SROC curve was 0.84 (95% CI:0.80-0.87) .The subgroup analysis showed that compared with immunohistochemistry, ELISA had higher positive likelihood ratio and diagnostic odds ratio and a larger area under the SROC curve, as well as a lower negative likelihood ratio.There was heterogeneity among the articles included, and the main sources of heterogeneity were different underlying liver diseases in patients, different types of diseases in non-primary liver cancer group (including benign control group and normal control group) , and difference in experimental design.The Deeks funnel plot showed no significant publication bias.Conclusion TGFβ1 has high sensitivity and specificity in the diagnosis of liver cancer and may become an auxiliary index for the diagnosis of liver cancer.
- liver neoplasms /
- transforming growth factor beta1 /
- diagnosis /
- meta-analysis

HTML全文

参考文献(25)

[1]CHEN W, ZHENG R, BAADE PD, et al.Cancer statistics in China, 2015[J].CA Cancer J Clin, 2016, 66 (2) :115-132.

[2]ARENDS JW.Molecular interactions in the vogelstein model of colorectal carcinoma[J].J Pathol, 2000, 190 (4) :412-416.

[3]MOURI H, SAKAGUCHI K, SAWAYAMA T, et al.Suppressive effects of transforming growth factor-beta1 produced by hepatocellular od mononuclear cells[J].Acta Med Okayama, 2002, 56 (6) :309-315.

[4]SHIRAI Y, KAWATA S, ITO N, et al.Elevated levels of plasma transforming growth factor-beta in patients with hepatocellula carcinoma cell lines on interferon-gamma production by peripheral blor carcinoma[J].Jpn J Cancer Res, 1992, 83 (7) :676.

[5]SHIRAI Y, KAWATA S, TAMURA S, et al.Plasma transforming growth factor-β1 in patients with hepatocellul arcarcinoma.Comparison with chronic liver disease[J].Cancer, 1994, 73:2275.

[6]SACCO R, LEUCI D, TORTORELLA C, et al.Transforming growth factor-β1 and soluble Fas serum levels in hepatocellular carcinoma[J].Cytokine, 2000, 12 (6) :811-814.

[7]FENG JH, LIU ZQ, WEI YY, et al.Diagnosis value of the joint test of serum GPC3 and TGFβ1 in AFP negative primary liver cancer patients[J].Int J Lab Med, 2015, 36 (19) :2787-2788. (in Chinese) 冯军花, 刘志权, 魏媛媛, 等.血清GPC3与TGFβ1联合检测对AFP阴性原发性肝癌的诊断价值[J].国际检验医学杂志, 2015, 36 (19) :2787-2788.

[8]GAN XT, BAI XG, HUANG TX, et al.Clinical significance of transforming growth factor-β1 in urine of patients with primary hepatic carcinoma[J].Med J Chin People's Armed Police Forces, 2003, 14 (9) :535-538. (in Chinese) 甘雪婷, 白宪光, 黄团新, 等.尿转化生长因子β1在原发性肝癌中的检测及临床意义[J].武警医学, 2003, 14 (9) :535-538.

[9]QIU LW, YAO DF, HUANG F, et al.Expression levels of TGFβ1, TNF-alpha and MMP-13 and their clinical values in patients with chronic liver diseases[J].J Nantong Univ:Med Sci, 2005, 25 (4) 244-246, 249. (in Chinese) 邱历伟, 姚登福, 黄峰, 等.慢性肝病患者转化生长因子-β1、肿瘤坏死因子-α和基质金属蛋白酶-13表达与临床价值[J].南通大学学报:医学版, 2005, 25 (4) :244-246, 249.

[10]SHAO Y, WANG ZR, LI F.The diagnostic value of transforming growth factor-β1 and alpha-fetoprotein L3 combined examination in hepatocellular carcinoma[J].J Mod Oncol, 2010, 18 (10) :2009-2012. (in Chinese) 邵渊, 王作仁, 李峰.转化生长因子-β1联合甲胎蛋白异质体二联检测对原发性肝癌诊断的意义[J].现代肿瘤医学, 2010, 18 (10) :2009-2012.

[11]XIAO WL, HA S, REN ZH, et al.Clinical value of combined detection of GP73, AFP-L3 and TGFβ1 in early diagnosis of hepatocellular carcinoma[J].Int J Lab Med, 2014, 35 (14) :1839-1841. (in Chinese) 肖伟利, 哈斯, 任志宏, 等.GP73、AFP-L3和TGFβ1联合检测在肝细胞癌早期诊断中的临床价值[J].国际检验医学杂志, 2014, 35 (14) :1839-1841.

[12]ZHANG CC, CHU RH, HAN P, et al.Diagnosis value analysis of serum AFP, GPC3, TGFβ1 single and combined testing on primary liver cancer[J].Qingdao Med J, 2012, 44 (2) :108-110. (in Chinese) 张彩彩, 褚瑞海, 韩鹏, 等.血清AFP、GPC3、TGFβ1单独及联合检测对原发性肝癌的诊断价值分析[J].青岛医药卫生, 2012, 44 (2) :108-110.

[13]TAI BJ, YAO DF, QIU LW, et al.Diagnostic value of circulating transforming growth factor-β1 and free insulin-like growth factor-II abnormalities for hepatocellular carcino ma[J].Clin Focus, 2007, 22 (24) :1757-1760. (in Chinese) 邰伯军, 姚登福, 邱历伟, 等.外周血转化生长因子β1和游离胰岛素样生长因子II异常与肝癌诊断[J].临床荟萃, 2007, 22 (24) :1757-1760.

[14]WU ZL, YAO DF, DONG ZZ, et al.Dignostic and differential diagnostic values of plasm-a transforming growth factor-β1 in patients with primary liver cancer[J].Chin J Gastroenterol Hepatol, 2004, 13 (5) :502-504. (in Chinese) 吴志兰, 姚登福, 董志珍, 等.转化生长因子-β1对原发性肝癌诊断与鉴别的临床价值[J].胃肠病学和肝病学杂志, 2004, 13 (5) :502-504.

[15]ZHANG D, LI Y, XU ZQ, et al.Clinical value of tumor marker in peripheral blood to the diagnosis of hepatocellular carcinoma[J].JChin Practical Diagn Ther, 2011, 25 (8) :742-744. (in Chinese) 张丹, 李远, 徐泽强, 等.外周血肝癌标志物在肝癌诊断中的价值[J].中华实用诊断与治疗杂志, 2011, 25 (8) :742-744.

[16]TSAI JF, JENG JE, CHUANG LY, et al.Elevated urinary transforming growth factor-beta1 level as a tumour marker and predictor of poor survival in cirrhotic hepatocellular carcinoma[J].Br J Cancer, 1997, 76 (2) :244-250.

[17]El-BASSIOUNY AE, ZOHEIRY MM, NOSSEIR MM, et al.Expression of cyclooxygenase-2 and transforming growth factor-beta1in HCV-induced chronic liver disease and hepatocellular carcinoma[J].Med Gen Med, 2007, 9 (3) :45.

[18]HE FY, ZHENG YL, WANG Y, et al.Clinical significance of TGF-β1 and PCNA expression in primary human hepatocarcinoma tissues[J].World Chin J Dig, 1998, 6 (7) :165-166. (in Chinese) 何凤云, 郑英兰, 王颖, 等.原发性肝癌组织TGFβ1和PCND的表达和意义[J].世界华人消化杂志, 1998, 6 (7) :165-166.

[19]KANG KF, SHI XC, CHEN XW, et al.Expression of PTTG and TGFβ1 with its receptor in hepatocellular carcinoma and their clinical significant[J].Chin J Cancer Prev Treat, 2007, 14 (6) :1223-1225. (in Chinese) 康凯夫, 石祥呈, 陈小伍, 等.肝癌组织中PTTG与TGFβ1及受体的表达及其临床意义[J].中华肿瘤防治杂志, 2007, 14 (6) :1223-1225.

[20]SHEN GD, JIANG RQ, SUN BC.Expressions of inflammation-associated factors IL-1β, TGF-βand MCP-1 in human hepatocellular carcinoma[J].Jiangsu Med J, 2011, 37 (7) :797-799. (in Chinese) 沈国定, 姜润秋, 孙倍成.炎症相关因子IL-1β, TGF-β及MCP-1在肝细胞肝癌的表达[J].江苏医药, 2011, 37 (7) :797-799.

[21]ZHAO W, LI ZY.The expression of Runx3、TGFβ1、β-catenin and Cyclin D1 in primary liver cancer and their correlation studies[D].Yinchuan:Ningxia Med Univ, 2012. (in Chinese) 赵伟, 李昭宇.Runx3、TGFβ1、β-catenin及Cyclin D1在原发性肝癌中的表达及相关性研究[D].银川:宁夏医科大学, 2012.

[22] ARENDS JW.Molecular interactions in the vogelstein model of colorectal carcinoma[J].J Pathol, 2000, 190 (4) :412-416.

[23]KIM KY, JEONG SY, WON J, et al.Induction of angiogenesis byexpression of soluble type II transforming growth factorbeta receptorinmouse hepatoma[J].J Biol Chem, 2001, 276 (42) :38781-38786.

[24]TAI BJ, YAO DF, ZOU L, et al.Dynamic expressions of transforming growth factor-β1 and tumor necrosis factor-αin hepatic oncogenesis[J].Chin J Gastroenterol Hepatol, 2006, 15 (3) :277-280. (in Chinese) 邰伯军, 姚登福, 邹黎, 等.肝细胞癌变过程中TGF-β1及TNFα的动态表达与改变[J].胃肠病学和肝病学杂志, 2006, 15 (3) :277-280.

[25]WANG Y, LIU T, TANG W, et al.Hepatocellular carcinoma cells induce regulatory T cells and lead to poor prognosis via production of transforming growth factor-β1[J].Cell Physiol Biochem, 2016, 38 (1) :306-318.

施引文献

资源附件(0)

访问统计